Vertical pathway inhibition overcomes adaptive feedback resistance to KRAS(G12C) inhibition

PURPOSE: Although KRAS represents the most commonly mutated oncogene, it has long been considered an “undruggable” target. Novel covalent inhibitors selective for the KRAS(G12C) mutation offer the unprecedented opportunity to target KRAS directly. However, prior efforts to target the RAS-MAPK pathwa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Ryan, Meagan B., de la Cruz, Ferran Fece, Phat, Sarah, Myers, David T., Wong, Edmond, Shahzade, Heather A., Hong, Catriona B., Corcoran, Ryan B.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7124991/
https://ncbi.nlm.nih.gov/pubmed/31776128
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-3523
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados